Success in Phase II trial for guselkumab for Psoriasis - Janssen
New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe Plaque Psoriasis receiving guselkumab (CNTO 1959) from Janssen Research & Development achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the study's primary endpoint.
The Phase IIb Janssen sponsored X-PLORE study demonstrated significantly higher levels of efficacy at all doses of guselkumab studied at week 16 when compared with the placebo group. Similar proportions of patients achieving a PGA score of cleared or minimal were observed at week 40 of the study. The trial also included an adalimumab arm.
The results also show that up to 86% of patients with moderate to severe Plaque Psoriasis who were treated with guselkumab had a Physician's Global Assessment (PGA) score of 0 or 1 versus 7% for placebo and 58% for Humira.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.